ML NIKKEI225 MITTS09 Earnings: Everything You Must Know Now

ML NIKKEI225 MITTS09 (NYSE:MNK) delivered a profit and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

ML NIKKEI225 MITTS09 Earnings Cheat Sheet


Revenue: Decreased 0% to $570 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: ML NIKKEI225 MITTS09 reported adjusted EPS income of $0.49 per share. By that measure, the company missed the mean analyst estimate of $0.79. It beat the average revenue estimate of $560.17 million.

Quoting Management: “Mallinckrodt’s third quarter results, our first as an independent, publicly traded company, reflect our stated strategy to focus our resources on transitioning the business into a leading specialty pharmaceuticals company,” said Mark Trudeau, President and CEO of Mallinckrodt. “Our Specialty Pharmaceuticals segment posted strong increases in net sales and operating income, benefiting from the sale of higher-margin branded and generic pharmaceutical products. Looking forward, we are optimistic about Mallinckrodt’s pipeline, which will enable us to bring to market important new drugs, further driving growth within our Specialty Pharmaceuticals segment. At the same time, we are committed to becoming more profitable by driving operating efficiencies throughout the Company. The restructuring program we are announcing today is part of that commitment.”

Key Stats (on next page)…

Revenue decreased 0% from $0 in the previous quarter.

Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0 to a profit $0.88. For the current year, the average estimate has moved up from a loss of $0 to a profit of $2.9 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]